Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Posizolid (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- 24 Jul 2017 Outcomes of a population pharmacokinetics model using patients (n=60) from this trial, designed for further dose optimization of AZD-5847, published in the Antimicrobial Agents and Chemotherapy Journal.
- 22 Aug 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 19 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.